{
  "articles": [
    {
      "path": "about.html",
      "title": "Brendan J. Kelly",
      "author": [],
      "contents": "\n\n          \n          \n          Brendan J. Kelly\n          \n          \n          About\n          Projects\n          \n          \n          Manuscripts\n           \n          ▾\n          \n          \n          Under Review\n          Publications\n          \n          \n          \n          \n          Teaching\n           \n          ▾\n          \n          \n          Intro to Epidemiology\n          Microbiome Measures\n          \n          \n          News\n          \n          \n          \n          \n          \n          \n          \n          \n          \n          \n          \n          \n          ☰\n          \n          \n      \n        \n          \n            \n              \n            \n              Brendan J. Kelly\n            \n            \n              \n                \n                    \n                      \n                        Twitter\n                      \n                    \n                  \n                                    \n                    \n                      \n                        GitHub\n                      \n                    \n                  \n                                    \n                    \n                      \n                        PubMed\n                      \n                    \n                  \n                                    \n                    \n                      \n                        CV\n                      \n                    \n                  \n                                  \n            \n          \n        \n        \n        \n          \n            Brendan J. Kelly, M.D., M.S., studies infectious diseases and epidemiology at the University of Pennsylvania. His research focuses on microbial ecosystems in humans at high risk for infection. Dr. Kelly seeks to understand properties of microbial ecosystems that protect against infection, how microbial ecosystems are altered by antibiotics, and how microbial ecosystems recover from infection and antibiotic treatment. He has performed large, clinical-translational studies to better understand pneumonia and intestinal infections that occur in the setting of critical illness. Dr. Kelly’s work has been supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Diseases Control and Prevention (CDC).\n            \n            Education\n            University of Pennsylvania | Philadelphia, PA\n            M.S. in Clinical Epidemiology | July 2011 - August 2013\n            Columbia University College of Physicians & Surgeons | New York, NY\n            M.D. | August 2002 - June 2007\n            Harvard University | Cambridge, MA\n            A.B. in History and Science | September 1998 - June 2002\n            \n            \n            Appointments\n            Assistant Professor of Medicine & Epidemiology | Perelman School of Medicine | University of Pennsylvania\n            Senior Scholar | Center for Clinical Epidemiology & Biostatistics | University of Pennsylvania\n            \n          \n        \n      \n    \n\n    \n      \n        \n          \n            \n              \n            \n              Brendan J. Kelly\n            \n            \n              \n                \n                                    \n                    \n                      Twitter\n                    \n                  \n                                    \n                    \n                      GitHub\n                    \n                  \n                                    \n                    \n                      PubMed\n                    \n                  \n                                    \n                    \n                      CV\n                    \n                  \n                                  \n              \n            \n            \n              Brendan J. Kelly, M.D., M.S., studies infectious diseases and epidemiology at the University of Pennsylvania. His research focuses on microbial ecosystems in humans at high risk for infection. Dr. Kelly seeks to understand properties of microbial ecosystems that protect against infection, how microbial ecosystems are altered by antibiotics, and how microbial ecosystems recover from infection and antibiotic treatment. He has performed large, clinical-translational studies to better understand pneumonia and intestinal infections that occur in the setting of critical illness. Dr. Kelly’s work has been supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Diseases Control and Prevention (CDC).\n              \n              Education\n              University of Pennsylvania | Philadelphia, PA\n              M.S. in Clinical Epidemiology | July 2011 - August 2013\n              Columbia University College of Physicians & Surgeons | New York, NY\n              M.D. | August 2002 - June 2007\n              Harvard University | Cambridge, MA\n              A.B. in History and Science | September 1998 - June 2002\n              \n              \n              Appointments\n              Assistant Professor of Medicine & Epidemiology | Perelman School of Medicine | University of Pennsylvania\n              Senior Scholar | Center for Clinical Epidemiology & Biostatistics | University of Pennsylvania\n              \n            \n        \n      \n    \n\n    \n    \n    ",
      "last_modified": "2021-10-02T13:23:24-04:00"
    },
    {
      "path": "index.html",
      "title": "Brendan J. Kelly",
      "author": [],
      "contents": "\n\n          \n          \n          Brendan J. Kelly\n          \n          \n          About\n          Projects\n          \n          \n          Manuscripts\n           \n          ▾\n          \n          \n          Under Review\n          Publications\n          \n          \n          \n          \n          Teaching\n           \n          ▾\n          \n          \n          Intro to Epidemiology\n          Microbiome Measures\n          \n          \n          News\n          \n          \n          \n          \n          \n          \n          \n          \n          \n          \n          \n          \n          ☰\n          \n          \n      \n        \n          \n            \n              \n            \n              Brendan J. Kelly\n            \n            \n              \n                \n                    \n                      \n                        PubMed\n                      \n                    \n                  \n                                    \n                    \n                      \n                        GitHub\n                      \n                    \n                  \n                                    \n                    \n                      \n                        CV\n                      \n                    \n                  \n                                    \n                    \n                      \n                        Twitter\n                      \n                    \n                  \n                                  \n            \n          \n        \n        \n        \n          \n            Brendan J. Kelly, M.D., M.S., is an infectious diseases physician and molecular epidemiologist at the University of Pennsylvania. He studies how microbes interact in the human respiratory and gastrointestinal tracts, and how microbial interactions can be engineered to prevent and treat antibiotic-resistant infections. Specifically, Dr. Kelly seeks to understand properties of microbial ecosystems that protect against bacterial pathogen colonization and infection, how microbial ecosystems are altered by antibiotics, and how they recover from infection and antibiotic treatment. He has performed large, clinical-translational studies to better understand two infections that occur commonly during critical illness: bacterial pneumonia and C. difficile colitis. He has also investigated the use of fecal microbiota transplant (FMT) to aid recovery of the intestinal microbiota after C. difficile treatment. During the COVID-19 pandemic, he is leading a study of SARS-CoV-2 variant succession across the Philadelphia metropolitan region. His work has been supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC).\n            \n            Education\n            University of Pennsylvania | Philadelphia, PA\n            M.S. in Clinical Epidemiology 2013\n            Columbia University | New York, NY\n            M.D. 2007\n            Harvard University | Cambridge, MA\n            A.B. in History and Science 2002\n            \n            \n            Appointments\n            Assistant Professor of Medicine & Epidemiology\n            Perelman School of Medicine | University of Pennsylvania\n            Senior Scholar\n            Center for Clinical Epidemiology & Biostatistics | University of Pennsylvania\n            \n            \n          \n        \n      \n    \n\n    \n      \n        \n          \n            \n              \n            \n              Brendan J. Kelly\n            \n            \n              \n                \n                                    \n                    \n                      PubMed\n                    \n                  \n                                    \n                    \n                      GitHub\n                    \n                  \n                                    \n                    \n                      CV\n                    \n                  \n                                    \n                    \n                      Twitter\n                    \n                  \n                                  \n              \n            \n            \n              Brendan J. Kelly, M.D., M.S., is an infectious diseases physician and molecular epidemiologist at the University of Pennsylvania. He studies how microbes interact in the human respiratory and gastrointestinal tracts, and how microbial interactions can be engineered to prevent and treat antibiotic-resistant infections. Specifically, Dr. Kelly seeks to understand properties of microbial ecosystems that protect against bacterial pathogen colonization and infection, how microbial ecosystems are altered by antibiotics, and how they recover from infection and antibiotic treatment. He has performed large, clinical-translational studies to better understand two infections that occur commonly during critical illness: bacterial pneumonia and C. difficile colitis. He has also investigated the use of fecal microbiota transplant (FMT) to aid recovery of the intestinal microbiota after C. difficile treatment. During the COVID-19 pandemic, he is leading a study of SARS-CoV-2 variant succession across the Philadelphia metropolitan region. His work has been supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC).\n              \n              Education\n              University of Pennsylvania | Philadelphia, PA\n              M.S. in Clinical Epidemiology 2013\n              Columbia University | New York, NY\n              M.D. 2007\n              Harvard University | Cambridge, MA\n              A.B. in History and Science 2002\n              \n              \n              Appointments\n              Assistant Professor of Medicine & Epidemiology\n              Perelman School of Medicine | University of Pennsylvania\n              Senior Scholar\n              Center for Clinical Epidemiology & Biostatistics | University of Pennsylvania\n              \n              \n            \n        \n      \n    \n\n    \n    \n    ",
      "last_modified": "2021-10-02T13:23:24-04:00"
    },
    {
      "path": "intro_epi.html",
      "title": "Introduction to Epidemiology",
      "author": [],
      "contents": "\n\n\n\nfitvids('.shareagain', {players: 'iframe'});\n\n\n\n\n",
      "last_modified": "2021-10-02T13:23:24-04:00"
    },
    {
      "path": "microbiome_measures.html",
      "title": "Measuring the Microbiome: Methods and Tools",
      "author": [],
      "contents": "\nMeasuring the Microbiome\n\n\n\nfitvids('.shareagain', {players: 'iframe'});\n\nSequences to Counts\n\n\n\nfitvids('.shareagain', {players: 'iframe'});\n\nAlpha Diversity\n\n\n\nfitvids('.shareagain', {players: 'iframe'});\n\nBeta Diversity\n\n\n\nfitvids('.shareagain', {players: 'iframe'});\n\nRegression Methods for Microbiome Data\n\n\n\nfitvids('.shareagain', {players: 'iframe'});\n\nMore Regression Methods for Microbiome Data\n\n\n\nfitvids('.shareagain', {players: 'iframe'});\n\n\n\n\n",
      "last_modified": "2021-10-02T13:23:25-04:00"
    },
    {
      "path": "news.html",
      "title": "",
      "author": [],
      "contents": "\n\n\n\n",
      "last_modified": "2021-10-02T13:23:25-04:00"
    },
    {
      "path": "projects.html",
      "title": "Projects",
      "author": [],
      "contents": "\n\n\n\nFecal microbiota transplantation to address colonization and environmental contamination with multidrug-resistant organisms (FACE-MDRO) (CDC U54-CK000610)\nWe will perform fecal microbiota transplantation (FMT) at the conclusion of antibiotic therapy for MDRO infections to define the impact of FMT on eradicating MDRO colonization from the gastrointestinal tract. We will also determine how FMT administration impacts MDRO colonization in the healthcare environment.\nWhole-genome sequencing to define SARS-CoV-2 variant populations during vaccine rollout in the Philadelphia metropolitan region (CDC BAA 200-2021-10986)\nWe are (1) performing longitudinal, geographic sampling of COVID-19 cases; (2) applying viral whole genome sequencing (WGS) and comparative phylogenetic analysis to cases; and (3) integrating longitudinal vaccine distribution and community mobility data with the viral WGS data to understand how the phylodynamics of SARS-CoV-2 change as COVID-19 vaccination expands.\nMetagenomic and whole-genome sequencing to define resistome evolution during antibiotic exposure and long-term acute care (CDC BAA 200-2018-02919)\nWe are applying metagenomic sequencing to raw respiratory and gastrointestinal tract specimens collected from a cohort of long-term acute care hospital (LTACH) patients with Pseudomonas aeruginosa colonization to understand how commonly prescribed antibiotics impact the microbiome and resistome, as well as the evolution of Pseudomonas colonization and antibiotic resistance.\nStool microbiome features to discriminate Clostridium difficile colonization and infection (CDC BAA 200-2016-91937)\nWe are performing a cross-sectional study to determine the bacterial microbiome features that discriminate C. difficile infection (CDI) from C. difficile colonization, as well as microbiome features associated with risk for severe CDI and recurrent CDI.\nRespiratory tract microbiome composition and risk for antibiotic-resistant lower respiratory infection during long-term acute care (CDC BAA 200-2016-91964)\nWe developed a cohort of long-term acute care (LTACH) patients dependent on mechanical ventilation and at high risk for lower respiratory tract infection and performed dense, longitudinal sampling of the upper and lower respiratory tract, as well as the gastrointestinal tract, in order to understand the evolution of the bacterial microbiome during critical illness and the microbiome features that portend risk for LRTI, thus improving the ability to target diagnostic and infection prevention interventions.\nRandomized clinical trial of fecal microbiota transplantation for severe and severe-complicated C.difficile infection (CDC Southestern Pennsylvania Adult and Pediatric Prevention Epicenter Network)\nA phase II, randomized trial to evaluate the safety and efficacy of fecal microbiota transplantation using the Penn Microbiome Therapy products for severe or severe-complicated/fulminate C.difficile infection (NCT03970200).\nLongitudinal analysis of respiratory tract microbiome change and sequence-based infection diagnosis during mechanical ventilation (K23 AI121485)\nBacterial pneumonia is a common and dangerous contributor to critical illness, during which patients depend on mechanical ventilators to assist their breathing. It may contribute to the initial need for mechanical ventilation, or it may complicate the course of mechanical ventilation. We are using deep sequencing methods to completely characterize the bacterial community of the respiratory tract over the full course of mechanical ventilation, thus improving understanding of how bacterial pneumonia occurs in critically ill patients, with implications for prevention, diagnosis, and treatment interventions.\n\n\n\n",
      "last_modified": "2021-10-02T13:23:25-04:00"
    },
    {
      "path": "publications.html",
      "title": "Publications",
      "author": [],
      "contents": "\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#gvauvhfbjv .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 11px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #000000;\n}\n\n#gvauvhfbjv .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #000000;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #000000;\n}\n\n#gvauvhfbjv .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#gvauvhfbjv .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 6px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#gvauvhfbjv .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n}\n\n#gvauvhfbjv .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#gvauvhfbjv .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 16px;\n  font-weight: bold;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#gvauvhfbjv .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 16px;\n  font-weight: bold;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#gvauvhfbjv .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#gvauvhfbjv .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#gvauvhfbjv .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#gvauvhfbjv .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #D3D3D3;\n  font-size: 100%;\n  font-weight: bold;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#gvauvhfbjv .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #D3D3D3;\n  font-size: 100%;\n  font-weight: bold;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n  vertical-align: middle;\n}\n\n#gvauvhfbjv .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#gvauvhfbjv .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#gvauvhfbjv .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #000000;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #000000;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #000000;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#gvauvhfbjv .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #000000;\n  padding-left: 12px;\n}\n\n#gvauvhfbjv .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#gvauvhfbjv .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n}\n\n#gvauvhfbjv .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#gvauvhfbjv .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n}\n\n#gvauvhfbjv .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#gvauvhfbjv .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n}\n\n#gvauvhfbjv .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#gvauvhfbjv .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#gvauvhfbjv .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#gvauvhfbjv .gt_sourcenote {\n  font-size: 11px;\n  padding: 4px;\n}\n\n#gvauvhfbjv .gt_left {\n  text-align: left;\n}\n\n#gvauvhfbjv .gt_center {\n  text-align: center;\n}\n\n#gvauvhfbjv .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#gvauvhfbjv .gt_font_normal {\n  font-weight: normal;\n}\n\n#gvauvhfbjv .gt_font_bold {\n  font-weight: bold;\n}\n\n#gvauvhfbjv .gt_font_italic {\n  font-style: italic;\n}\n\n#gvauvhfbjv .gt_super {\n  font-size: 65%;\n}\n\n#gvauvhfbjv .gt_footnote_marks {\n  font-style: italic;\n  font-weight: normal;\n  font-size: 65%;\n}\nAuthors\n      Title\n      Journal\n      Link\n      Year\n    Rhee RL, Lu J, Bittinger K, Lee J-J, Mattei LM, Sreih AG, Chou S, Miner JJ, Cohen NA, Kelly BJ, Lee H, Grayson PC, Collman RG, Merkel PA\nDynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis\nArthritis Rheumatol\nhttp://dx.doi.org/10.1002/art.41723\n2021Kelly BJ, Bekele S, Loughrey S, Huang E, Tolomeo P, David MZ, Lautenbach E, Han JH, Ziegler MJ, CDC Prevention Epicenters Program\nHealthcare microenvironments define multidrug-resistant organism persistence\nInfect Control Hosp Epidemiol\nhttp://dx.doi.org/10.1017/ice.2021.323\n2021Harrigan JJ, Abdallah H, Clarke EL, Oganisian A, Roy JA, Lautenbach E, Reesey E, Wernovsky M, Tolomeo P, Morawski Z, Jacob J, Grippi MA, Kelly BJ\nRespiratory microbiome disruption and risk for ventilator-associated lower respiratory tract infection\nClin Infect Dis\nhttp://dx.doi.org/10.1093/cid/ciab678\n2021Abdallah HO, Weingart MF, Fuller R, Pegues D, Fitzpatrick R, Kelly BJ\nSubglottic suction frequency and adverse ventilator-associated events during critical illness\nInfect Control Hosp Epidemiol\nhttp://dx.doi.org/10.1017/ice.2020.1298\n2021Richard-Greenblatt M, Ziegler MJ, Bromberg V, Huang E, Abdallah H, Tolomeo P, Lautenbach E, Glaser L, Kelly BJ\nQuantifying the Impact of Nasopharyngeal Specimen Quality on Severe Acute Respiratory Syndrome Coronavirus 2 Test Performance\nOpen Forum Infect Dis\nhttp://dx.doi.org/10.1093/ofid/ofab235\n2021Redding LE, Kelly BJ, Stefanovski D, Lautenbach JK, Tolomeo P, Cressman L, Gruber E, Meily P, Lautenbach E\nPet Ownership Protects Against Recurrence of Clostridioides difficile Infection\nOpen Forum Infect Dis\nhttp://dx.doi.org/10.1093/ofid/ofz541\n2020Berry ASF, Kelly BJ, Barnhart D, Kelly DJ, Beiting DP, Baldassano RN, Redding LE\nGut microbiota features associated with Clostridioides difficile colonization in puppies\nPLoS One\nhttp://dx.doi.org/10.1371/journal.pone.0215497\n2019Ziegler M, Han JH, Landsburg D, Pegues D, Reesey E, Gilmar C, Gorman T, Bink K, Moore A, Kelly BJ, CDC Prevention Epicenters Program\nImpact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy\nOpen Forum Infect Dis\nhttp://dx.doi.org/10.1093/ofid/ofz252\n2019Knecht VR, McGinniss JE, Shankar HM, Clarke EL, Kelly BJ, Imai I, Fitzgerald AS, Bittinger K, Bushman FD, Collman RG\nMolecular analysis of bacterial contamination on stethoscopes in an intensive care unit\nInfect Control Hosp Epidemiol\nhttp://dx.doi.org/10.1017/ice.2018.319\n2019Kelly BJ, Lautenbach E, Nachamkin I, Coffin SE, Gerber JS, Fuchs BD, Garrigan C, Han X, Bilker WB, Wise J, Tolomeo P, Han JH, Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program\nCombined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis\nCrit Care Med\nhttp://dx.doi.org/10.1097/CCM.0000000000003137\n2018Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y, Umscheid CA\nNewer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis\nClin Microbiol Infect\nhttp://dx.doi.org/10.1016/j.cmi.2017.08.028\n2018Kelly BJ, Tebas P\nClinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection\nChest\nhttp://dx.doi.org/10.1016/j.chest.2017.09.002\n2018Kelly BJ, Lautenbach E, Nachamkin I, Coffin SE, Gerber JS, Fuchs BD, Garrigan C, Han X, Bilker WB, Wise J, Tolomeo P, Han JH, Centers for Disease Control and Prevention (CDC) Prevention Epicenters Program\nCombined biomarkers discriminate a low likelihood of bacterial infection among surgical intensive care unit patients with suspected sepsis\nDiagn Microbiol Infect Dis\nhttp://dx.doi.org/10.1016/j.diagmicrobio.2016.01.003\n2016Kelly BJ, Imai I, Bittinger K, Laughlin A, Fuchs BD, Bushman FD, Collman RG\nComposition and dynamics of the respiratory tract microbiome in intubated patients\nMicrobiome\nhttp://dx.doi.org/10.1186/s40168-016-0151-8\n2016Kelly BJ, Gross R, Bittinger K, Sherrill-Mix S, Lewis JD, Collman RG, Bushman FD, Li H\nPower and sample-size estimation for microbiome studies using pairwise distances and PERMANOVA\nBioinformatics\nhttp://dx.doi.org/10.1093/bioinformatics/btv183\n2015Brady T, Kelly BJ, Male F, Roth S, Bailey A, Malani N, Gijsbers R, O’Doherty U, Bushman FD\nQuantitation of HIV DNA integration: effects of differential integration site distributions on Alu-PCR assays\nJ Virol Methods\nhttp://dx.doi.org/10.1016/j.jviromet.2013.01.004\n2013Khiabanian H, Holmes AB, Kelly BJ, Gururaj M, Hripcsak G, Rabadan R\nSigns of the 2009 influenza pandemic in the New York-Presbyterian Hospital electronic health records\nPLoS One\nhttp://dx.doi.org/10.1371/journal.pone.0012658\n2010Yu M, Kumar TRS, Nkrumah LJ, Coppi A, Retzlaff S, Li CD, Kelly BJ, Moura PA, Lakshmanan V, Freundlich JS, Valderramos J-C, Vilcheze C, Siedner M, Tsai JH-C, Falkard B, Sidhu ABS, Purcell LA, Gratraud P, Kremer L, Waters AP, Schiehser G, Jacobus DP, Janse CJ, Ager A, Jacobs WR Jr, Sacchettini JC, Heussler V, Sinnis P, Fidock DA\nThe fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites\nCell Host Microbe\nhttp://dx.doi.org/10.1016/j.chom.2008.11.001\n2008\n\n\n\n\n",
      "last_modified": "2021-10-02T13:23:30-04:00"
    },
    {
      "path": "under_review.html",
      "title": "Under Review",
      "author": [],
      "contents": "\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#gvauvhfbjv .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 11px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #000000;\n}\n\n#gvauvhfbjv .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #000000;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #000000;\n}\n\n#gvauvhfbjv .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#gvauvhfbjv .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 6px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#gvauvhfbjv .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n}\n\n#gvauvhfbjv .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#gvauvhfbjv .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 16px;\n  font-weight: bold;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#gvauvhfbjv .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 16px;\n  font-weight: bold;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#gvauvhfbjv .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#gvauvhfbjv .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#gvauvhfbjv .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#gvauvhfbjv .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #D3D3D3;\n  font-size: 100%;\n  font-weight: bold;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#gvauvhfbjv .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #D3D3D3;\n  font-size: 100%;\n  font-weight: bold;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n  vertical-align: middle;\n}\n\n#gvauvhfbjv .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#gvauvhfbjv .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#gvauvhfbjv .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #000000;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #000000;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #000000;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#gvauvhfbjv .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #000000;\n  padding-left: 12px;\n}\n\n#gvauvhfbjv .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#gvauvhfbjv .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n}\n\n#gvauvhfbjv .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#gvauvhfbjv .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n}\n\n#gvauvhfbjv .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#gvauvhfbjv .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #000000;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #000000;\n}\n\n#gvauvhfbjv .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#gvauvhfbjv .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#gvauvhfbjv .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#gvauvhfbjv .gt_sourcenote {\n  font-size: 11px;\n  padding: 4px;\n}\n\n#gvauvhfbjv .gt_left {\n  text-align: left;\n}\n\n#gvauvhfbjv .gt_center {\n  text-align: center;\n}\n\n#gvauvhfbjv .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#gvauvhfbjv .gt_font_normal {\n  font-weight: normal;\n}\n\n#gvauvhfbjv .gt_font_bold {\n  font-weight: bold;\n}\n\n#gvauvhfbjv .gt_font_italic {\n  font-style: italic;\n}\n\n#gvauvhfbjv .gt_super {\n  font-size: 65%;\n}\n\n#gvauvhfbjv .gt_footnote_marks {\n  font-style: italic;\n  font-weight: normal;\n  font-size: 65%;\n}\nAuthors\n      Title\n      Category\n    Brendan J. Kelly, MD, MS; Ebbing Lautenbach, MD, MPH, MSCE; Jason Roy, PhD; Ayannah S. Fitzgerald, BSN; Layla A. Khatib, BS; Ize Imai, MS; Leigh Cressman, MA; Frederic D. Bushman, PhD; Ronald G. Collman, MD \nInterspecific interactions define respiratory Staphylococcus aureus infection risk during mechanical ventilation\nMicrobial Ecology of Bacterial Infection; Molecular Epidemiology of Infectious Diseases; Antibiotic and Healthcare Impacts on the Human Microbiome\nMatthew J. Ziegler, MD, MS; Elizabeth Huang; Selamawit Bekele; Emily Reesey, MS; Pam Tolomeo, MPH, Sean Loughrey, MS; Michael Z. David, MD, PhD; Ebbing Lautenbach, MD, MPH, MS; Brendan J. Kelly, MD, MS for the CDC Prevention Epicenters Program\nSpatial and temporal effects on SARS-CoV-2 contamination of the healthcare environment\nSpatial Epidemiology of Infectious Diseases; Molecular Epidemiology of Infectious Diseases\nAndrew Marques, Scott Sherrill-Mix, John Everett, Shantan Reddy, Pascha Hokama, Aoife M. Roche, Young Hwang, Abigail Glascock, Samantha A. Whitesides, Jevon Grahan-Wooten, Layla A. Khatib, Ayannah S. Fitzgerald, Ahmed Moustafa, Paul Planet, Nitika Badjatia, Zi-Xuan Wang, Carolyn Cannuscio, Katie Strelau, Arupa Ganguly, Mike Feldman, Ronald G. Collman, Kyle Rodino, Brendan Kelly, and Frederic Bushman\nSARS-COV-2 variants associated with vaccine breakthrough in the Delaware River Valley\nMolecular Epidemiology of Infectious Diseases; Novel Infectious Diseases Diagnostics; Spatial Epidemiology of Infectious Diseases\n\n\n\n\n\n",
      "last_modified": "2021-10-02T13:23:32-04:00"
    }
  ],
  "collections": ["posts/posts.json"]
}
